Guardant Health, Inc. (GH)

How it makes money

Guardant Health generates revenue through three channels: (1) clinical testing services sold directly to oncology practices and cancer centers, reimbursed by commercial payers and government programs (Medicare/Medicaid) at negotiated or statutory rates; (2) biopharmaceutical collaborations where the company provides test development, clinical trial support, and real-world genomic data licensing to pharmaceutical companies developing cancer therapeutics; (3) other services including tissue testing and development services. Revenue depends on test volume, reimbursement rates negotiated with payers, companion diagnostic approvals enabling tied test-drug relationships, and international expansion. The company faces reimbursement variability as payers make independent coverage decisions and can adjust rates prospectively or retrospectively.

Revenue by segment

Guardant's competitive advantages rest on regulatory approval status, proprietary sequencing technology, and accumulated genomic data—but these face erosion risks. FDA approvals for Guardant360 CDx and Shield blood test for colorectal screening create defensible entry barriers; the Shield approval was the first for primary colorectal cancer screening blood test, and 21 state biomarker-testing mandates institutionalize demand for therapy selection testing. The company's patent portfolio covers sequencing methods and disease detection algorithms, though patents expire between 2026 and 2041, with the earliest expirations creating vulnerability. The GuardantINFORM platform provides a data advantage from accumulated genomic and clinical outcomes linked to specific drugs—difficult to replicate but not insurmountable. Companion diagnostic approvals (28 CDx approvals) create physician-adoption network effects and sticky pharmaceutical partnerships. However, the moat is narrow: competitors like Foundation Medicine (Roche), Exact Sciences, Natera, and Quest have entered liquid biopsy with comparable platforms, and the company's non-CDx tests lack the same regulatory defensibility.

Demand for cancer diagnostics is defensive and not sensitive to macroeconomic cycles; cancer diagnosis prevalence and treatment decisions are driven by disease biology and clinical guidelines, not economic activity. However, reimbursement flows can fluctuate based on payer policies and government budget cycles. The company benefits from structural tailwinds: an aging population increasing cancer incidence, expansion of personalized medicine therapies requiring molecular testing (number of FDA-approved cancer drugs with biomarker requirements continues to grow), low colorectal cancer screening penetration (59% of eligible adults), and state mandates in 21 states requiring biomarker testing for specific cancers. Demand is sensitive to clinical guideline endorsements and KOL (key opinion leader) adoption.

Key risks

• Reimbursement Uncertainty — The company depends on payer coverage decisions and reimbursement rates, which are unpredictable and subject to retroactive adjustment. Commercial payers and Medicare can prospectively and retrospectively reduce payment rates or seek recovery of prior payments. The Shield colorectal screening test is newly approved and faces variable payer coverage expansion. Even though Medicare increased Guardant360 LDT reimbursement to $5,000 in 2024, future rate cuts or non-coverage decisions could materially impact revenue.
• Significant Operating Losses and Cash Burn — Guardant reported net losses of $436 million in 2024, down from $479 million in 2023 but reflecting continued cash burn despite strong revenue growth (31% YoY). The company has accumulated a deficit of $2.6 billion since inception. Free cash flow burn was $275 million in 2024. Without achieving profitability or substantial positive cash flow, the company faces risks to equity value and financing flexibility, and the path to breakeven remains uncertain.
• Competitive Intensity — Guardant competes with well-capitalized rivals including Foundation Medicine (Roche subsidiary), Exact Sciences, Natera, NeoGenomics, Laboratory Corporation of America, Quest Diagnostics, and emerging players like Tempus AI and Caris Life Science. Competitors are expanding liquid biopsy platforms, pursuing companion diagnostics, and investing in screening products. Competitive pricing pressure and market share loss pose ongoing risks.
• Supply Chain Concentration — Guardant relies on Illumina as the primary supplier of sequencing instruments and reagents. The supply agreement runs through January 2033 with automatic renewal. While the company maintains multi-month safety stock, disruptions to Illumina's operations, supply constraints, price increases, or termination of the relationship could materially disrupt Guardant's testing volume and profitability.
• Regulatory and Patent Expiration Risks — The FDA's regulatory approach to laboratory-developed tests (LDTs) remains uncertain; tighter oversight could increase compliance costs or restrict product availability. The company's patent portfolio expires between 2026 and 2041, with some patents expiring as early as 2026, enabling competitors to enter protected markets. LDT regulatory enforcement discretion and potential FDA action could subject Shield and other LDTs to stricter requirements.

The filing does not disclose a quantified customer concentration percentage. The company references tracking of designated customers (Customer A, B, C) in XBRL financial data, but no single customer is identified as representing 10% or more of revenue based on narrative disclosures. The customer base is fragmented across clinical payers (Medicare, Medicaid, commercial insurance), oncology practices, biopharmaceutical partners, and international laboratories. The company notes dependence on biopharmaceutical relationships as a key revenue source but does not identify any individual biopharma customer as material.